Intervention not reported
Mosquito mortality (unwashed nets) · Anopheles gambiae complex or Anopheles funestus group
The intervention showed no clear difference in mosquito mortality (unwashed nets) (low certainty).
1 finding from 1 review
RR 1.2 [0.64, 2.26]
Studies not reported
Low
Intervention not reported
Mosquito mortality (washed nets) · Anopheles gambiae complex or Anopheles funestus group
The intervention showed no clear difference in mosquito mortality (washed nets) (low certainty).
1 finding from 1 review
RR 1.07 [0.92, 1.25]
Studies not reported
Low
Intervention not reported
Blood‐feeding success (unwashed nets) · Anopheles gambiae complex or Anopheles funestus group
It is very uncertain whether the intervention changes blood‐feeding success (unwashed nets) (very low certainty).
1 finding from 1 review
RR 0.52 [0.12, 2.22]
Studies not reported
Very low
Intervention not reported
Blood‐feeding success (washed nets) · Anopheles gambiae complex or Anopheles funestus group
It is very uncertain whether the intervention changes blood‐feeding success (washed nets) (very low certainty).
1 finding from 1 review
RR 1.25 [0.82, 1.91]
Studies not reported
Very low
Intervention not reported
Mosquito mortality (unwashed nets) · adults and childen living in malaria‐endemic areas, Anopheles gambiae complex or Anopheles funestus group
The intervention leads to higher mosquito mortality (unwashed nets) (high certainty).
1 finding from 1 review
Intervention not reported
Mosquito mortality (washed nets) · adults and childen living in malaria‐endemic areas, Anopheles gambiae complex or Anopheles funestus group
It is very uncertain whether the intervention changes mosquito mortality (washed nets) (very low certainty).
1 finding from 1 review
Intervention not reported
Blood‐feeding success (unwashed nets) · adults and childen living in malaria‐endemic areas, Anopheles gambiae complex or Anopheles funestus group
The intervention leads to lower blood‐feeding success (unwashed nets) (high certainty).
1 finding from 1 review
Intervention not reported
Blood‐feeding success (washed nets) · adults and childen living in malaria‐endemic areas, Anopheles gambiae complex or Anopheles funestus group
The intervention leads to lower blood‐feeding success (washed nets) (high certainty).
1 finding from 1 review
Intervention not reported
Mosquito mortality (unwashed nets) · Anopheles gambiae complex or Anopheles funestus group
The intervention probably leads to higher mosquito mortality (unwashed nets) (moderate certainty).
1 finding from 1 review
RR 1.68 [1.33, 2.11]
Studies not reported
Moderate
Death due to any cause · adults with mild to severe COVID‐19
Hydroxychloroquine (HCQ) showed no clear difference in death due to any cause compared with standard care or placebo (high certainty).
1 finding from 1 review
Participants with any adverse events · people who have been exposed to SARS‐CoV‐2
Hydroxychloroquine (HCQ) probably leads to higher participants with any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Participants with serious adverse events · people who have been exposed to SARS‐CoV‐2
1 finding from 1 review
Negative PCR for SARS‐CoV‐2 on respiratory samples at day 14 from enrolmentd · adults with mild to severe COVID‐19
Hydroxychloroquine (HCQ) showed no clear difference in negative PCR for SARS‐CoV‐2 on respiratory samples at day 14 from… compared with standard care or placebo (low certainty).
1 finding from 1 review
Progression to mechanical ventilation · adults with mild to severe COVID‐19
Hydroxychloroquine (HCQ) showed no clear difference in progression to mechanical ventilation compared with standard care or placebo (moderate certainty).
1 finding from 1 review
Time to clinical improvement · adults with mild to severe COVID‐19
It is very uncertain whether hydroxychloroquine (HCQ) changes time to clinical improvement compared with standard care or placebo (very low certainty).
1 finding from 1 review
Participants with any adverse events · adults with mild to severe COVID‐19
Hydroxychloroquine (HCQ) probably leads to higher participants with any adverse events compared with standard care or placebo (moderate certainty).
1 finding from 1 review
Participants with serious adverse events · adults with mild to severe COVID‐19
Hydroxychloroquine (HCQ) showed no clear difference in participants with serious adverse events compared with standard care or placebo (low certainty).
1 finding from 1 review
Participants with prolongation of QT‐interval on ECG · adults with mild to severe COVID‐19
It is very uncertain whether hydroxychloroquine (HCQ) changes participants with prolongation of QT‐interval on ECG compared with standard care or placebo (very low certainty).
1 finding from 1 review
Development of confirmed COVID‐19 at 14 days from enrolment · people who have been exposed to SARS‐CoV‐2
It is very uncertain whether hydroxychloroquine (HCQ) changes development of confirmed COVID‐19 at 14 days from enrolment compared with placebo (very low certainty).
1 finding from 1 review
Hospitalized due to COVID‐19c · people who have been exposed to SARS‐CoV‐2
It is very uncertain whether hydroxychloroquine (HCQ) changes hospitalized due to COVID‐19c compared with placebo (very low certainty).
1 finding from 1 review